Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens

AIDS Research and Human Retroviruses

Volumn 31, Issue 2, 2015, Pages 221-228

  Munger, Alana M ^a   Chow, Dominic C ^a   Playford, Martin P ^b   Parikh, Nisha I ^a   Gangcuangco, Louie Mar A ^a   Nakamoto, Beau K ^a,c   Kallianpur, Kalpana J ^a   Ndhlovu, Lishomwa C ^a   Shikuma, Cecilia M ^a   Mehta, Nehal N ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c STRAUB CLINIC AND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPOPROTEIN;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; ATHEROSCLEROSIS; BLOOD; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT;

ANTI-RETROVIRAL AGENTS; ATHEROSCLEROSIS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84923226375     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0239     Document Type: Article

References (33)

1. Funderburg, NT, Zidar DA, Shive, C, Lioi A, Mudd J, Musselwhite LW, Simon DI, Costa MA, Rodriguez B, Sieg SF, and Lederman MM: Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012;120:4599-4608.
2. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, and Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-1052.
3. Giannarelli C, Klein RS, and Badimon JJ: Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis 2011;219:384-389.
4. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD, and the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
5. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, and Lundgren JD: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
6. Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, and Gulick RM: Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 2007;44:540-550.
7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs JR Jr, Bangdiwala S, and Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
8. Cotter AG, Satchell CS, O'Halloran JA, Feeney ER, Sabin CA, and Mallon PWG: High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. AIDS 2011;25:867-869.
9. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, and Weintraub W: Niacin in Patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
10. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, and Gelfand JM: Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012;224:218-221.
11. Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, Mehta NN, and Dokras A: Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab 2014;99:E841-847.
12. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, and Ridker PM: Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010;59:1153-1160.
13. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, and Ridker PM: Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-939.
14. Duffy D and Rader DJ: Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009;6:455-463.
15. Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E, Caracas-Portilla NA, Cardoso-Saldaña G, Medina-Urrutia A, Jorge-Galarza E, and Juárez-Rojas JG: Cholesterol efflux and metabolic abnormalities associated with low highdensity-lipoprotein-cholesterol and high triglycerides in statin-Treated coronary men with low-density lipoproteincholesterol 70 mg/dl. Am J Cardiol 2012 109 636-641
16. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, and Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364: 127-135.
17. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, and Hazen SL: Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-1705.
18. Khera AV and Rader DJ: Cholesterol efflux capacity: Full steam ahead or a bump in the road?. Arterioscler Thromb Vasc Biol 2013;33:1449-1451.
19. Shikuma CM, Seto T, Liang CY, Bennett K, DeGruttola V, Gerschenson M, Stein JH, Budoff M, Hodis HN, Delaney JA, Ogata-Arakaki D, Pramyothin P, and Chow D: Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses 2012;28:793-797.
20. Sciacqua A, Perticone M, Grillo N, Falbo T, Bencardino G, Angotti E, Arturi F, Parlato G, Sesti G, and Perticone F: Vitamin D and 1-hour post-load plasma glucose in hypertensive patients. Cardiovasc Diabetol 2014;13:48.
21. Matsuda M and DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22: 1462-1470.
22. Barbour JD, Jalbert EC, Chow DC, Gangcuangco LMA, Norris PJ, Keating SM, Heitman J, Nagamine L, Seto T, Ndhlovu LC, Nakamoto BK, Hodis HN, Parikh NI, and Shikuma CM: Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy. Atherosclerosis 2014;232:52-58.
23. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, and Goff DC Jr: Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011;5:105-113.
24. Stein JH, Komarow L, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Parker RA, Torriani FJ, theACTG 5152s Study Team: Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s Stein: Lipoprotein changes on antiretroviral therapy. J Clin Lipidol 2008;2:464-471.
25. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD, the INSIGHT SMART Study Group: Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009;207:524-529.
26. Fan J, Qi Y, and Zhao D: [A meta-Analysis on the association between high-density lipoprotein particle subfractions and cardiovascular disease events]. Zhonghua Xin Xue Guan Bing Za Zhi 2014;42:57-61.
27. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyörälä K, and Penttilä I: Serum lipids and lipoproteins in middle-Aged non-insulin-dependent diabetics. Atherosclerosis 1985;56: 271-281.
28. Borggreve SE, De Vries R, and Dullaart RPF: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-1069.
29. den Boer MA, Berbée JF, Reiss P, van der Valk M, Voshol PJ, Kuipers F, Havekes LM, Rensen PC, and Romijn JA: Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 2006;26:124-129.
30. Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, and Semenkovich CF: Visceral adiposity, C-peptide levels, and low lipase activities predict HIVdyslipidemia. Am J Physiol Endocrinol Metab 2003;285: E899-905.
31. Nikkilä EA: High density lipoproteins in diabetes. Diabetes 1981;30:82-87.
32. Rader DJ and Tall AR: The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?. Nat Med 2012;18:1344-1346.
33. Heinecke JW: The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?. Nat Med 2012; 18:1346-1347.